Also known as: Mavyret (with Pibrentasvir)
Glecaprevir is a pan-genotypic HCV NS3/4A protease inhibitor used in combination with pibrentasvir for the treatment of chronic hepatitis C virus infection across all major genotypes. Mediocon Inc supplies pharmaceutical-grade Glecaprevir API.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | ≥98.0% (as per pharmacopoeia) |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Glecaprevir (CAS 1365970-03-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Glecaprevir is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance